肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2009年
7期
472-474
,共3页
乳腺肿瘤%拓扑异构酶Ⅱa%TTC%FTC%抗肿瘤联合化疗方案
乳腺腫瘤%拓撲異構酶Ⅱa%TTC%FTC%抗腫瘤聯閤化療方案
유선종류%탁복이구매Ⅱa%TTC%FTC%항종류연합화료방안
Breast neoplasms%Chemotherapy%Topoisomerase Ⅱa%TIC%FTC%Antineoplastic combined chemotherapy protocols
目的 比较新辅助化疗方案TTC及FTC治疗乳腺癌的疗效.方法 收集325例乳腺癌新辅助化疗患者的资料,其中TTC方案138例、FTC方案187例,并采用免疫组织化学法检测所有患者化疗前活组织检查标本Topo Ⅱ a的表达状况.结果 TTC组、FTC组乳腺癌总缓解率(RR)分别为87.7%、67.4%.两组差异有统计学意义(P=0.000);而分层分析显示:在TopoⅡa(-)组,TTC、FTC两组患者RR差异均有统计学意义,而TopoⅡa(+)Her-2(-)组,FTC组为79.4%,TTC组为87.8%,差异无统计学意义(P=0.266);TTC组、FTC组患者的病理完全缓解率分别为13.7%、11.2%,差异无统计学意义(P=0.491).结论 新辅助化疗TTC较FTC方案有较高的缓解率;而对于TopoⅡa(-)患者,应用或联合紫杉类药物治疗可能取得更好的疗效.
目的 比較新輔助化療方案TTC及FTC治療乳腺癌的療效.方法 收集325例乳腺癌新輔助化療患者的資料,其中TTC方案138例、FTC方案187例,併採用免疫組織化學法檢測所有患者化療前活組織檢查標本Topo Ⅱ a的錶達狀況.結果 TTC組、FTC組乳腺癌總緩解率(RR)分彆為87.7%、67.4%.兩組差異有統計學意義(P=0.000);而分層分析顯示:在TopoⅡa(-)組,TTC、FTC兩組患者RR差異均有統計學意義,而TopoⅡa(+)Her-2(-)組,FTC組為79.4%,TTC組為87.8%,差異無統計學意義(P=0.266);TTC組、FTC組患者的病理完全緩解率分彆為13.7%、11.2%,差異無統計學意義(P=0.491).結論 新輔助化療TTC較FTC方案有較高的緩解率;而對于TopoⅡa(-)患者,應用或聯閤紫杉類藥物治療可能取得更好的療效.
목적 비교신보조화료방안TTC급FTC치료유선암적료효.방법 수집325례유선암신보조화료환자적자료,기중TTC방안138례、FTC방안187례,병채용면역조직화학법검측소유환자화료전활조직검사표본Topo Ⅱ a적표체상황.결과 TTC조、FTC조유선암총완해솔(RR)분별위87.7%、67.4%.량조차이유통계학의의(P=0.000);이분층분석현시:재TopoⅡa(-)조,TTC、FTC량조환자RR차이균유통계학의의,이TopoⅡa(+)Her-2(-)조,FTC조위79.4%,TTC조위87.8%,차이무통계학의의(P=0.266);TTC조、FTC조환자적병리완전완해솔분별위13.7%、11.2%,차이무통계학의의(P=0.491).결론 신보조화료TTC교FTC방안유교고적완해솔;이대우TopoⅡa(-)환자,응용혹연합자삼류약물치료가능취득경호적료효.
Objective To investigate the efficacy of TTC and FTC regimens as neoadjuvant chemotherapy in breast cancer. Methods Collecting clinical data of 325 patients received neoadjuvant chemotherapy with TIC and FTC regimens from June 2004 to April 2008, among them 138 patients received neoadjuvant chemotherapy with TTC regimen in one group, and 187 patients received neoadjuvant chemotherapy with CTF regimen in the other group. The expression of Topo Ⅱ a in specimen of 325 patients before neoadjuvant chemotherapy were detected by immunohistochemical method. Results Among the 325 cases of neoadjuvant chemotherapy, the overall response rate (RR) was 87.7 % in TIC arm and 67.4 % in FTC arm (P=0.000), but in the group of Topo Ⅱ a(+) Her-2(-), the overall response rate (RR) was 87.8 % in TTC arm and 79.4 % in FTC arm (P=0.266), and in the groups of Topo Ⅱ a(-), there was statistical significance; the pathologic complete response rate (pCR) was 13.7 % in TIC ann and 11.2 % in CTF ann (P=0.491). Conclusion TIC regimen is superior to FTC regimen in the response rate of neoadjuvant chemotherapy, but patients with negative expression of Topo Ⅱ a may get more benefits from 9eoadjuvant taxane and anthracycline chemotherapy.
